The short version
4 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Morphine Sulfate
Morphine Sulfate · MORPHINE SULFATE 80 mg/1 · Capsule, Extended Release · Oral · Amneal Pharmaceuticals of New York LLC
NDC 00115-1281-08 · 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE · ANDA · View full market →
Medicare Part D
All Part D pricing →Matched to CMS's representative package for this drug (NDC 00832-0230-00) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
ⓘ How this was built
Data sources
- CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Plans pay at point of saleⓘ
$12.10per unit
middle half $7.73–$22.03 · 91 plans · Apr 1, 2026
Est. net of rebatesⓘ
≈ $12.10
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
2%of plans cover it
tier 4 · prior auth 0% · step therapy 12% · qty limit 74%
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.1%chance of a new FDA shortage posting for morphine sulfate (oral solid) in the next 90 days
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Where it's made
- Amneal Pharmaceuticals of New York, LLCUnited Statesanalysis · label · manufacture · pack
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $28.78 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program · Opioid Analgesic REMS Shared System REMS
Regulatory
- Application
- ANDA200411
- TE code
- —
- Approval date
- Apr 12, 2016
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Morphine Sulfate (Capsule, Extended Release)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Actavis Pharma, Inc. | MORPHINE SULFATE 90 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Actavis Pharma, Inc. | MORPHINE SULFATE 120 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Actavis Pharma, Inc. | MORPHINE SULFATE 30 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Actavis Pharma, Inc. | MORPHINE SULFATE 45 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Actavis Pharma, Inc. | MORPHINE SULFATE 60 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Actavis Pharma, Inc. | MORPHINE SULFATE 75 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Amneal Pharmaceuticals of New York LLC | MORPHINE SULFATE 80 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Amneal Pharmaceuticals of New York LLC | MORPHINE SULFATE 50 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Amneal Pharmaceuticals of New York LLC | MORPHINE SULFATE 30 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Amneal Pharmaceuticals of New York LLC | MORPHINE SULFATE 60 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Amneal Pharmaceuticals of New York LLC | MORPHINE SULFATE 20 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Amneal Pharmaceuticals of New York LLC | MORPHINE SULFATE 100 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Amneal Pharmaceuticals of New York LLC | MORPHINE SULFATE 40 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Nortec Development Associates, Inc. | MORPHINE SULFATE 20 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Nortec Development Associates, Inc. | MORPHINE SULFATE 30 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Nortec Development Associates, Inc. | MORPHINE SULFATE 80 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Nortec Development Associates, Inc. | MORPHINE SULFATE 50 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Nortec Development Associates, Inc. | MORPHINE SULFATE 60 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Nortec Development Associates, Inc. | MORPHINE SULFATE 100 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Upsher-Smith Laboratories, LLC | MORPHINE SULFATE 10 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Upsher-Smith Laboratories, LLC | MORPHINE SULFATE 60 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Upsher-Smith Laboratories, LLC | MORPHINE SULFATE 30 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Upsher-Smith Laboratories, LLC | MORPHINE SULFATE 20 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Upsher-Smith Laboratories, LLC | MORPHINE SULFATE 100 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Upsher-Smith Laboratories, LLC | MORPHINE SULFATE 80 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Upsher-Smith Laboratories, LLC | MORPHINE SULFATE 50 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Morphine Sulfate — NDC 00115-1281-08," retrieved September 3, 2026, https://drugdashboards.com/drug/00115128108.
Free to cite with attribution — see how the data is put together.